ILLUMINA, INC. — fact timeline

Daniel M. Skovronsky was appointed as Director at ILLUMINA, INC..

“On June 16, 2026, the Board of Directors (the “Board”) of Illumina, Inc. (the “Company”) increased the size of the Board from nine to ten members and appointed Daniel M. Skovronsky, M.D., Ph.D., to serve on the Board, effective immediately.”

ILLUMINA, INC. shareholders approved Advisory approval of compensation paid to named executive officers at the 2026-05-21 meeting.

“3. On an advisory basis, approval of the compensation paid to the Company's "named executive officers" as disclosed in the Company's Proxy Statement for the Annual Meeting. This proposal was approved.”

ILLUMINA, INC. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending January 3, 2027 at the 2026-05-21 meeting.

“2. The ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending January 3, 2027. This proposal was approved.”

ILLUMINA, INC. shareholders approved Election of nine director nominees to hold office until the 2027 annual meeting at the 2026-05-21 meeting.

“1. The election of each of the following nominees to the Board of Directors to hold office for one year until the annual meeting of stockholders in the year 2027: Caroline Dorsa, Scott Gottlieb, David King, Keith Meister, Anna Richo, Philip Schiller, Susan Siegel, Jacob Thaysen and Scott Ullem. Each of the nominees has been elected to the Board of Directors.”

ILLUMINA, INC. reported first quarter ended March 29, 2026 results: revenue $1.09 billion, EPS $0.87. Guidance raised.

“Inc. (Nasdaq: ILMN) (“Illumina” or the “company”) today announced its financial results for the first quarter of fiscal year 2026. First quarter 2026 results: • Revenue of $1.09 billion for Q1 2026 , up 4.8% from Q1 2025 (ROW 1 organic revenue growth of 3.5%) • GAAP operating margin of 19.2% and non-GAAP operating margin of 21.9% • GAAP diluted EPS of $0.87 and”

ILLUMINA, INC. completed an acquisition involving Standard BioTools Inc. for $350,000,000 in cash (closed 2026-01-30).

“BioTools’s mass cytometry and microfluidics businesses (the “Business”). On January 30, 2026, the Company completed the Transaction. The Company paid a purchase price of $350,000,000 in cash, subject to customary adjustments. The Purchase Agreement further provides for, in connection with the revenues generated from certain products and services, (i) royalty”

Keith A. Meister was elected as Director at ILLUMINA, INC..

“On March 25, 2025, the Board elected Keith A. Meister to serve on the Board beginning March 28, 2025.”

Stephen P. MacMillan resigned as Director at ILLUMINA, INC..

“On March 25, 2025, Stephen P. MacMillan, notified the Board of Directors (the “Board”) of Illumina, Inc. (the “Company”) of his intention to resign as a director of the Company, effective as of March 28, 2025.”

Carissa Rollins departed as Chief Information Officer at ILLUMINA, INC..

“On March 18, 2025, Carissa Rollins, Chief Information Officer, notified Illumina, Inc. that she will be retiring effective as of April 11, 2025.”

ILLUMINA, INC. announced a restructuring with charges of $32 million affecting Foster City campus and another property in San Diego, California.

“The Company recorded right-of-use asset and leasehold improvement impairment charges of $32 million in the first fiscal quarter of 2024 related to these exits.”

Scott Davies was appointed as Interim General Counsel and Secretary at ILLUMINA, INC..

“As of the Effective Date, Scott Davies, Vice President, Legal – Chief Corporate Counsel and Assistant Secretary, will serve as Interim General Counsel and Secretary.”

Charles Dadswell departed as General Counsel and Secretary at ILLUMINA, INC..

“Charles Dadswell, the Company’s General Counsel and Secretary, will leave Illumina.”

ILLUMINA, INC. completed a disposition involving GRAIL, Inc. for pro rata distribution of one share of GRAIL common stock for every six shares of Illumina common stock (closed 2024-06-24).

“As previously reported, effective as of 12:01 New York City time on June 24, 2024 (the “Distribution Date”), Illumina completed the pro rata distribution to holders of record of Illumina’s common stock, par value $0.01 per share (“Illumina Common Stock”), as of 5:00 p.m. New York City time on June 13, 2024 (the “Record Date”), of one share of GRAIL common stock, par value $0.001 per share (“GRAIL Common Stock”), for every six shares of Illumina Common Stock held by such Illumina stockholders as of the Record Date (the “Distribution”).”

ILLUMINA, INC. announced a impairment with charges of $420 million affecting GRAIL.

“the Company estimates that it will recognize an impairment charge for the GRAIL IPR&D intangible asset in the second quarter of 2024 equal to $420 million”

ILLUMINA, INC. announced a impairment with charges of $1,466 million affecting GRAIL.

“the Company estimates that it will recognize a goodwill impairment charge in the second quarter of 2024 equal to $1,466 million, or the full remaining carrying value of goodwill related to GRAIL as of March 31, 2024”

ILLUMINA, INC. completed a disposition involving GRAIL, Inc. (closed 2024-06-24).

“At 12:01 a.m. New York time on the Distribution Date, Illumina effected the Distribution and completed the separation of GRAIL from Illumina.”

ILLUMINA, INC. announced a impairment with charges of potential indicator of impairment in the second quarter of 2024 for purposes of performing an interim goodwill impairment test, which could result in the recogn affecting GRAIL, LLC.

“Additionally, the approval of the Spin-Off by Illumina’s board of directors represents a potential indicator of impairment in the second quarter of 2024 for purposes of performing an interim goodwill impairment test, which could result in the recognition of an impairment.”

ILLUMINA, INC. announced a restructuring with charges of incremental charges of approximately $35 - $50 million, primarily comprised of cash expenditures relating to legal and advisory fees affecting Spin-Off.

“In connection with the Spin-Off (as defined and described below), Illumina, Inc. (the “Company” or “Illumina”) estimates that it will incur incremental charges of approximately $35 - $50 million, primarily comprised of cash expenditures relating to legal and advisory fees.”

ILLUMINA, INC. announced a impairment with charges of additional right-of-use asset impairments of $18 million in Q1 2024 related to our campus in Foster City, California and another property in San Diego, Californ affecting our campus in Foster City, California and another property in San Diego, California.

“The Company recorded additional right-of-use asset impairments of $18 million in Q1 2024 related to our campus in Foster City, California and another property in San Diego, California. The Company also recorded $14 million of leasehold improvement impairments related to our Foster City campus in Q1 2024.”

ILLUMINA, INC. announced a impairment with charges of $43 million affecting Foster City campus.

“The company recorded right-of-use asset and leasehold improvement impairment charges of $43 million in the fourth fiscal quarter of 2023 related to that exit.”

ILLUMINA, INC. updated its first quarter ended March 31, 2024 guidance (reaffirmed).

“On May 2, 2024, Illumina, Inc. (the "Company") issued a press release announcing financial results for the first quarter ended March 31, 2024.”

ILLUMINA, INC. updated its first quarter 2024 and full-year 2024 guidance (reaffirmed).

“The company has reaffirmed its guidance for the first quarter 2024 and full-year 2024, as announced during its fourth quarter 2024 earnings call on February 8, 2024.”

Ankur Dhingra was appointed as Chief Financial Officer at ILLUMINA, INC..

“Ankur Dhingra has been appointed Chief Financial Officer of the Company, effective April 15, 2024”

Joydeep Goswami departed as Chief Financial Officer at ILLUMINA, INC..

“Joydeep Goswami has decided to leave Illumina. He will stay on in an advisory role through June 30 to support two new executive management team appointments.”

ILLUMINA, INC. reported financial results for the fourth quarter and fiscal year ended December 31, 2023.

“On February 8, 2024, Illumina, Inc. (the "Company") issued a press release announcing financial results for the fourth quarter and fiscal year ended December 31, 2023.”

ILLUMINA, INC. reported preliminary financial results for the fourth quarter and fiscal year ended December 31, 2023.

“Illumina Announces Preliminary Financial Results for Fourth Quarter and Fiscal Year 2023”

ILLUMINA, INC. announced a impairment with charges of approximately $43 million affecting Foster City campus.

“and now estimates that it will incur right-of-use asset and leasehold improvement impairment charges of approximately $43 million in the fourth fiscal quarter of 2023 related to this exit.”

Bas Verhoef was appointed as Chief Commercial Officer at ILLUMINA, INC..

“Bas Verhoef, Head of Region – Europe, will serve as Interim Chief Commercial Officer”

Susan Tousi departed as Chief Commercial Officer at ILLUMINA, INC..

“Susan Tousi, Chief Commercial Officer, will be leaving the Company effective as of January 5, 2024”

ILLUMINA, INC. announced a impairment with charges of approximately $54 million affecting i3 campus in San Diego, California.

“the Company incurred right-of-use asset and leasehold improvement impairment charges of approximately $54 million in 2023 related to the exit of its i3 campus in San Diego, California.”

ILLUMINA, INC. reported the third quarter ended October 1, 2023 results: revenue $1,119, net income $(754), EPS $0.33. Guidance lowered.

“and drive stronger execution.” Third quarter consolidated results GAAP Non-GAAP (a) Dollars in millions, except per share amounts Q3 2023 Q3 2022 Q3 2023 Q3 2022 Revenue $ 1,119 $ 1,115 $ 1,119 $ 1,115 Gross margin 61.1 % 64.3 % 65.4 % 68.4 % Research and development (“R&D”) expense $ 315 $ 325 $ 312 $ 324 Selling, general and administrative (“SG&A”)”

ILLUMINA, INC. shareholders approved advisory proposal regarding the frequency of advisory votes on executive compensation at the 2023-05-25 meeting.

“Based on the voting results on the advisory proposal regarding the frequency of advisory votes on executive compensation, the Company has decided that it will continue to include an advisory vote on executive compensation in the Company’s proxy statement every one (1) year”

Phil Febbo departed as Chief Medical Officer at ILLUMINA, INC..

“Phil Febbo, Chief Medical Officer, departed the company on August 7, 2023.”

Charles Dadswell changed role as Senior Vice President and General Counsel at ILLUMINA, INC..

“Mr. Dadswell will continue to serve as the Company’s Senior Vice President and General Counsel following the Commencement Date.”

ILLUMINA, INC. reported the second quarter ended July 2, 2023 results: revenue $1.18 billion. Guidance reaffirmed.

“+1.858.291.6421 ir@illumina.com Media: David McAlpine +1.347.327.1336 pr@illumina.com Illumina Reports Financial Results for Second Quarter of Fiscal Year 2023 • Revenue of $1.18 billion for Q2 2023, up 1% from Q2 2022 (up 3% on a constant currency basis) and up 8% from Q1 2023 • Shipped 109 NovaSeq X instruments in Q2 2023; boosting our supply capacity to more”

Steve Barnard was appointed as Chief Technology Officer at ILLUMINA, INC..

“the appointment of Dr. Steve Barnard as the Company’s new Chief Technology Officer, effective immediately”

Alex Aravanis departed as Chief Technology Officer at ILLUMINA, INC..

“on August 9, 2023, the Company announced that Dr. Alex Aravanis, who has served as Chief Technology Officer, will also depart the Company.”

Phil Febbo departed as Chief Medical Officer at ILLUMINA, INC..

“On August 7, 2023, Dr. Phil Febbo, Chief Medical Officer, departed Illumina, Inc. (the “Company”),”

ILLUMINA, INC. announced a restructuring with charges of approximately $25 - $35 million (headcount reduction).

“Company has committed to reduce its annualized run rate expenses by more than $100 million in 2023. The Company estimates that it will incur aggregate charges of approximately $25 - $35 million in connection with the reduction in force commenced on June 21, 2023, and additional reductions this year. The Company expects that the majority of these charges”

Charles Dadswell was appointed as Chief Executive Officer at ILLUMINA, INC..

“the Board appointed Charles Dadswell, the Company’s current Senior Vice President and General Counsel, to serve as interim Chief Executive Officer, effective immediately”

Francis deSouza resigned as Chief Executive Officer at ILLUMINA, INC..

“On June 11, 2023, the Board of Directors (the “Board”) of Illumina, Inc. (the “Company”) accepted the resignation of Francis deSouza, which Mr. deSouza submitted to the Board on June 8, 2023, as Chief Executive Officer and as a director of the Company, effective immediately”

Scott B. Ullem was elected as Director at ILLUMINA, INC..

“elected Stephen P. MacMillan and Scott B. Ullem to serve on the Board beginning June 1, 2023.”

Stephen P. MacMillan was elected as non-executive Chair of the Board at ILLUMINA, INC..

“Mr. MacMillan will serve as non-executive Chair of the Board.”

ILLUMINA, INC. shareholders approved Approval of certain amendments to the Illumina, Inc. 2015 Stock and Incentive Plan at the 2023-05-25 meeting.

“Proposal 5 Votes regarding the approval of certain amendments to the Illumina, Inc. 2015 Stock and Incentive Plan: For Against Abstain 119,428,365 7,325,826 4,242,445”

ILLUMINA, INC. shareholders approved Advisory approval of the frequency of holding an advisory vote to approve executive compensation at the 2023-05-25 meeting.

“Proposal 4 Votes regarding the approval, on an advisory basis, of the frequency of holding an advisory vote to approve the compensation provided to our “named executive officers”: 1 Year 2 Years 3 Years Abstain 127,627,051 189,271 648,698 2,531,616”

ILLUMINA, INC. shareholders rejected Advisory approval of the compensation paid to the named executive officers at the 2023-05-25 meeting.

“Proposal 3 Votes regarding the approval, on an advisory basis, of the compensation paid to the Company’s “named executive officers” as disclosed in the Company’s Proxy Statement for the Annual Meeting were: For Against Abstain 18,170,980 109,292,943 3,532,713”

ILLUMINA, INC. shareholders approved Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm at the 2023-05-25 meeting.

“Proposal 2 Votes regarding the ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023, were: For Against Abstain 122,532,962 5,707,584 2,756,090”

ILLUMINA, INC. shareholders approved Election of nine nominees to the Board of Directors at the 2023-05-25 meeting.

“Proposal 1 Votes regarding the election of nine director nominees were: Company Nominees For Withheld Frances Arnold, Ph.D. 124,546,729 6,451,478 Francis A. deSouza 93,110,014 37,883,131 Caroline D. Dorsa 119,897,382 11,097,368 Robert S. Epstein. M.D. 99,998,500 30,994,645 Scott Gottlieb, M.D. 124,491,952 6,502,798 Gary S. Guthart. Ph.D. 119,243,640 11,751,109 Philip W. Schiller 124,403,402 6,591,347 Susan E. Siegel 124,711,201 6,283,549 John W. Thompson 45,091,516 85,899,687 Icahn Group Nominees For Withheld Vincent J. Intrieri 35,131,099 95,855,921 Jesse A. Lynn 11,638,156 119,348,803 Andrew J. Teno 77,769,509 53,217,511”

ILLUMINA, INC. reported the first quarter ended April 2, 2023 results: revenue $1.09 billion, net income $3, EPS $0.02. Guidance reaffirmed.

“Illumina Reports Financial Results for First Quarter of Fiscal Year 2023; Announces Commitment to Accelerate Margin Growth • Revenue of $1.09 billion for Q1 2023, up 1% from Q4 2022; down 11% from Q1 2022 (down 9% on a constant currency basis) • GAAP diluted EPS of $0.02 for Q1 2023, compared to GAAP diluted EPS of $0.55 for Q1 2022 • Non-GAAP diluted EPS of $0.08 for Q1 2023, compared to non-GAAP diluted EPS of $1.07 for Q1 2022”

ILLUMINA, INC. reported Fiscal Year 2023 results: EPS $0.03 to $0.28 per share. Guidance initiated.

“For fiscal year 2023, expect revenue to grow 7% to 10% compared to fiscal year 2022, GAAP diluted earnings per share of $0.03 to $0.28, and non-GAAP diluted earnings per share of $1.25 to $1.50”